Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med
Daniels D, Grytdal S, Wasley A. Centers for disease C, prevention. Surveillance for acute viral hepatitis—United States, 2007. MMWR Surveill Summ
Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med
Conjeeveram HS, Fried MW, Jeffers JL, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology
Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology
Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med
Jensen DM, Marcellin P, Freilich B, et al. Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med
Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res
Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res
Pfeffer LM. Biologic activities of natural and synthetic type I interferons. Semin Oncol. 1997;24:S9-63-S9-9.
Erickson AK, Seiwert S, Gale M Jr. Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection. Antivir Ther
Kaiser S, Hass H, Gregor M. Successful retreatment of peginterferon nonresponder patients with chronic hepatitis C with high dose consensus interferon induction therapy [abstract 214]. Presented at the digestive disease week 2003, Orlando, FL, USA, 17–22 May 2003. Gastroenterology. 2003;124:A-700.
Leevy C, Chalmers C, Blatt LM. Comparison of African American and non African American patient end of treatment response for PEG-IFN alpha 2+ weight-based ribavirin nonresponders retreated with IFN alfacon-1+ weight-based ribavirin [abstract 172]. Presented at the 55th annual meeting of the American Association for the Study of Liver Diseases, Boston, MA, USA, 29 October–2 November 2004. Hepatology. 2004;40:240A.
Leevy CB. Consensus interferon and ribavirin in patients with chronic hepatitis C who were nonresponders to pegylated interferon alfa-2b and ribavirin. Dig Dis Sci
Kaiser S, Hass HG, Lutze B, Gregor M. Comparison of daily consensus interferon versus peginterferon α -2a extended therapy of 72 weeks for peginterferon/ribavirin relapse patients with chronic hepatitis C [abstract 1060]. Presented at the digestive disease week 2006, Los Angeles, CA, USA, 20–25 May 2006. Gastroenterology. 2006;130:A784.
Rothstein KR, Koka R, Fernandez A, Hargrove H, Singh S, Araya V, Munoz SJ. Successful treatment with high dose consensus interferon and ribavirin of patients with chronic hepatitis C who are resistant to peg-interferon and ribavirin therapy [abstract 1926]. Presented at the digestive disease week 2006, Los Angeles, CA, USA, 20–25 May 2006. Gastroenterology. 2006;130:A286.
Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology
Kaiser S, Lutze B, Hass HG. Treatment of peginterferon/ribavirin nonresponders with daily dosing of consensus interferon and ribavirin: results from the German Consensus Interferon Multicenter Study [abstract 1866]. Presented at the 59th annual meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, USA, 31 October–4 November 2008. Hepatology. 2008;48:1143A.
Berg C, Goncales FL Jr, Bernstein DE, et al. Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. J Viral Hepat
Kaiser S, Lutze B, Hass HG, Werner CR. High sustained virologic response rates in HCV genotype 1 relapser patients retreated with peginterferon alfa-2A (40KD) plus ribavirin for 72 weeks [abstract 1806]. Presented at the 59th annual meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, USA, 31 October–4 November 2008. Hepatology. 2008;48:1140A.
Pearlman BL, Ehleben C. Retreatment of chronic hepatitis C-genotype 1-infected relapsers to peginterferon/ribavirin with consensus interferon/ribavirin or with extended duration therapy peginterferon/ribavirin [abstract 815]. Presented at the 60th annual meeting of the American Association for the Study of Liver Diseases, Boston, MA, USA, 30 October–1 November 2009. Hepatology. 2009;50:686A.
Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology
Ghany MG, Lok AS, Everhart JE, et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology
Gonzalez SA, Keeffe EB. Management of chronic hepatitis C treatment failures: role of consensus interferon. Biol Targets Therapy. 2009;3:141–150.